Результаты поиска

CXCL13 как биомаркер: фон и полезность в многоразовом склерозе.

CXCL13 — хемокин, регулируемый в рамках CNS в множестве склерозов, нейроборлиозе Лайма и других подстрекательских болезнях, который все чаще используется в качестве биомаркера. Этот обзор служит основой для понимания его функций в иммунной системе и его связи с эктическими лимфоидными фолликулами. Кроме того, был рассмотрен вопрос о его полезности в случае множественного склероза и нейроборлиоза Лайма, а также потенциальные проблемы в его измерении. CXCL13 может быть исключительно полезным биомаркером для целого ряда подстрекательских заболеваний.

B-cell targeted therapeutics in clinical development.

B lymphocytes are the source of humoral immunity and are thus a critical component of the adaptive immune system. However, B cells can also be pathogenic and the origin of disease. Deregulated B-cell function has been implicated in several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. B cells contribute to pathological immune responses through the secretion of cytokines, costimulation of T cells, antigen presentation, and the production of autoantibodies. DNA-and RNA-containing immune complexes can also induce the production of type

Характеристики, режим лечения и результаты лечения пациентов с истинной экстрамеуллярной множественной миеломой: реальный моноцентрический анализ.

Несмотря на значительные терапевтические достижения в области множественной миеломы (ММ), экстрамеуллярные заболевания (ЭМД) по-прежнему являются агрессивным подтипом, связанным с плохим прогнозом, в отношении которого отсутствует консенсус в отношении управления и не хватает специальных клинических испытаний. Мы провели ретроспективный одноцентральный анализ 86 пациентов с радиологически подтвержденными ЭМД, определяемыми как участие в мягких тканях без континуитета кости (отсечение данных в сентябре) 30, 2024). В группу входили пациенты с де ново ЭМД (n = 19, 22%) и вторичного ЭМД при рециди

A prognostic index for multiple myeloma.

The current prognostic systems have failed to identify multiple myeloma (MM) patients who require aggressive therapy. These staging systems do not reliably distinguish patients with different prognoses. This paper explores the possibility of improving the prognostic forecast in MM by considering some clinical characteristics at diagnosis together with response to first-line chemotherapy. A total of 231 patients were prospectively randomised in a multicentre trial to no therapy vs melphalan + prednisone (MP) for stage I, MP in stage II, and MP vs peptichemio, vincristine and prednisone for stag

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

AbstractLineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic

Совпадение в полном тексте источника
… The other 2 cases began as B-ALL, 1 of which developed a T-cell/myeloid MPAL 41 and 1 with evolution to plasmablastic lymphoma, first in multiple EMD sites and eventually in the bone marrow 40 ( Table 4 ). … Beyond the more common presentation of B-ALL to a myeloid phenotype, we also report on 5 rare immunophenotypes of LS (3 T-ALL to AML, 1 B-ALL to T/myeloid MPAL, and 1 B-ALL to plasmablastic lymphoma) and 10 cases of lineage drift, to designate an incomplete or potentially more evanescent change in immunophenotype …

Liver failure due to relapsed myeloma and hepatic iron overload.

Multiple myeloma is a hematologic malignancy that classically manifests with hypercalcaemia, renal insufficiency, anaemia and lytic bone lesions. Liver dysfunction in multiple myeloma is a lesser known complication that occurs through biliary obstruction, liver infiltration by plasma cells, amyloid/light chain deposition or due to liver injury from medications. Although transfusion-related hepatic iron overload-leading to significant liver disease-is a recognised complication in certain hematologic malignancies, little is known about transfusional iron overload in patients with multiple myelom

CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.

Although current treatments for autoimmune diseases can effectively control symptoms, they rarely lead to cures and often require lifelong use, accompanied by considerable adverse effects. This emphasizes the urgent need for more targeted therapies that offer long-term efficacy and curative potential. Chimeric antigen receptor (CAR) T-cell therapy presents a promising option by specifically targeting and eliminating autoreactive B cells, with the potential to reset the patient's immune system and promote long-term immune balance. Originally developed for treating hematologic malignancies, wher

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Diagnoses included: diffuse large B cell lymphoma (DLBCL) not otherwise specified 38.9% (n=7); DLBCL transformation of indolent lymphoma 27.8% (n=5); Angioimmunoblastic T-cell Lymphoma 11.1% (n=2); and single cases of Peripheral T-cell lymphoma, not otherwise specified; Plasmablastic lymphoma; DLBCL …

Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?

BackgroundGeneralized myasthenia gravis (gMG) is a heterogeneous autoimmune disorder marked by antibody-mediated disruption of neuromuscular transmission. Despite advancements in immunosuppressive therapies and biologics, a subset of patients remains refractory, necessitating more targeted and personalized treatment strategies.ObjectiveThis review aims to synthesize current knowledge of the immunopathological mechanisms across gMG subtypes and to explore emerging therapeutic targets tailored to these diverse disease phenotypes.MethodsA narrative review was conducted, integrating recent finding

Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations.

Multiple myeloma and monoclonal gammopathy of undetermined significance are plasma cell dyscrasias characterized by monoclonal proliferation of pathological plasma cells with uncontrolled production of immunoglobulins. Autoimmune pathologies are conditions in which T and B lymphocytes develop a tendency to activate towards self-antigens in the absence of exogenous triggers. The aim of our review is to show the possible correlations between the two pathological aspects. Molecular studies have shown how different cytokines that either cause inflammation or control the immune system play a part i

Помимо рецидивов: как ингибиторы BTK определяют будущее прогрессивного лечения MS.

Множественный склероз является биологически и клинически гетерогенным воспламенительным демиелинизирующим заболеванием, движущимся реанимирующими и прогрессивными механизмами, причем все люди испытывают разную степень и то, и другое. Существующая высокоэффективная терапия направлена на периферийные воспаления и снижает частоту рецидивов, но имеет ограниченную эффективность в прогрессивных MS из-за слабого проникновения мозгового барьера в кровь и неспособности справиться с нейродегенерацией. Тирозиновые киназы Брютона (BTK) представляют собой новый терапевтический класс, предлагающий новый мех

Cerebrospinal Fluid sCD27 в качестве биомаркера неевроинфламационной болезни: систематический обзор и мета-анализ.

Нейровоспалительные заболевания центральной нервной системы (ЦНС) создают значительные диагностические проблемы из-за переплетения клинических характеристик и отсутствия конкретных биомаркеров, способных надежно обнаруживать воспаление CNS. Растворимый CD27 (SCD27) — маркер адаптивной иммунной активации, выпущенный на CD27-CD70 SCD27 стал многообещающим биомаркером цереброспиновой жидкости (CSF), однако его клиническая полезность остается неясной. Цель этого систематического обзора и метаанализа заключалась в уточнении диагностического значения CSF SCD27 в нейронных условиях. Мы систематически

Cellular therapies for rheumatic disease.

PURPOSE OF REVIEW: Cellular therapies, particularly chimeric antigen receptor (CAR)-modified lymphocytes, have progressed from experimental oncology into serious consideration for selected autoimmune rheumatic diseases. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of deep, drug-free remission in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. This timely article reviews the rationale, current clinical experience, safety profile, and

Long-term treatment outcome of Castleman's disease: A real-world experience.

BACKGROUND: Castleman disease (CD), classified as unicentric CD (UCD) or multicentric CD (MCD), is a rare non-neoplastic lymphoproliferative disorder of unknown origin. Owing to its rarity, the clinical characteristics, therapeutic modalities, treatment outcomes, and prognostic factors related to UCD or MCD are not well defined. METHOD: We retrospectively analyzed 88 patients with CD, including those with hyaline-vascular, plasma-cell, mixed type, hypervascular, and plasmablastic subtypes, for presenting symptoms, physical, laboratory, and radiologic findings, and treatment response in the Ko

Sp140L функционирует как фактор ограничения герпесвируса, подавляющий вирусную транскрипцию и активирующий интерферонально-стимулированные гены.

Герпесвирусы, включая вирус Эпштейн-Барр (ЭБВ), - человеческий онкогенный вирус и важнейший пусковой механизм множественного склероза, - должны обходить механизмы ДНК-разведки, чтобы установить пожизненную скрытую инфекцию. Поэтому герпесвирусы кодируют вирусные белки, чтобы разрушить ключевые факторы, связанные с зондированием ДНК и вирусным ограничением. Первый вирусный белок латентности, выраженный EBNA-LP, крайне важен для преобразования наивных клеток B и установления вирусного генного экспрессии, однако его роль в уклонении от защиты хостов остается неясной. Используя одноклеточную после

Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis.

Primary bone lymphoma (PBL) is a rare neoplasm of malignant lymphoid cells presenting with one or more bone lesions without nodal or other extranodal involvement. It accounts for approximately 1% of all lymphomas and 7% of malignant primary bone tumors. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) represents the predominant histological type and constitutes over 80% of all cases. PBL may occur at all ages with a typical diagnosis age of 45-60 years and a slight male predominance. Local bone pain, soft tissue edema, palpable mass and pathological fracture are the most co

Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis.

Myasthenia Gravis (MG) is a chronic disabling autoimmune disease caused by autoantibodies to the neuromuscular junction (NMJ), characterized clinically by fluctuating weakness and early fatigability of ocular, skeletal and bulbar muscles. Despite being commonly considered a prototypic autoimmune disorder, MG is a complex and heterogeneous condition, presenting with variable clinical phenotypes, likely due to distinct pathophysiological settings related with different immunoreactivities, symptoms' distribution, disease severity, age at onset, thymic histopathology and response to therapies. Cur

TAFRO syndrome: current perspectives.

Multicentric Castleman's disease (MCD), a distinct subtype of Castleman's disease, is a rare, nonneoplastic, lymphoproliferative disorder. Patients with MCD present with systemic symptoms and multiple lymphadenopathy. Lymph node biopsy is necessary for the diagnosis of various histological MCD patterns including hyaline vascular, plasma cell, and mixed types. Human herpesvirus 8 (HHV8) infection was identified as an important etiology of MCD among immunocompromised patients such as those positive for human immunodeficiency virus. Although HHV8-negative MCD was reported in immunocompetent patie

A Rare Case of Epidural Myeloma Presenting as Recurrent Subdural Bleeding.

Multiple myeloma (MM) is an incurable clonal B-cell malignancy that usually presents with neoplastic monoclonal plasma cells in either bone or soft tissues. Central nervous system involvement of the myeloma (CNS-MM), such as dural myeloma or intraparenchymal infiltration, or diffuse leptomeningeal involvement, is uncommon. Dural involvement of myeloma without parenchymal or leptomeningeal disease is even rarer, with only seven cases reported previously. We present a case of epidural myeloma in a 50-year-old man with known kappa light chain MM, presenting with multiple episodes of subdural hemo

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.

BACKGROUND: Plasma cell myeloma (PCM) is a neoplasm of terminally differentiated B lymphocytes with molecular heterogeneity. Although therapy-related myeloid neoplasms are common in plasma cell myeloma patients after chemotherapy, transdifferentiation of plasma cell myeloma into myeloid neoplasms has not been reported in literature. Here we report a very rare case of myeloid neoplasm transformed from plasma cell myeloma. CASE PRESENTATION: A 60-year-old man with a history of plasma cell myeloma with IGH-MAF gene rearrangement and RAS/RAF mutations developed multiple soft tissue lesions one ye